Status:
UNKNOWN
A Study of CSPCHA131 in Patients With Advanced Solid Tumor
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The study was designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of CSPCHA131 alone or plus chemotherapy in patients with advanced solid tumors.
Detailed Description
This is a dose escalation and expansion study with the aim to evaluate and characterize the tolerability and safety profile of CSPCHA131 alone (Stage I) or plus chemotherapy (Stage II) in patients wit...
Eligibility Criteria
Inclusion
- 18-75 years of age.
- 2\. Histologically or cytologically confirmed diagnosis of advanced or metastatic malignant solid tumors, for which standard therapy either does not exist or has been proven ineffective or intolerable for the patient.
- 3\. At least one measurable tumor lesion according to RECIST version 1.1.
- 4\. ECOG performance status of 0 or 1.
- 5\. Life expectancy ≥ 3 months. No cardiac insufficiency or serious abnormalities in the electrocardiogram at baseline.
Exclusion
- 1\. Administration of chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, other anti-tumor treatments or an investigational drug within 4 weeks or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
- 2\. Have undergone surgery within 4 weeks prior to the study treatment or have not fully recovered from any previous invasive procedure.
- 3\. Adverse reactions to previous anti-tumor treatments that levels have not recovered to grade 1 or less.
- 4\. Patients with evidence of uncontrolled nervous system metastasis or meningeal metastases, in the opinion of the investigator, not suitable for enrollment.
- 5\. Active infections of grade 2 or above.
- 6\. Peripheral neuropathy of grade 2 or above.
Key Trial Info
Start Date :
April 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 12 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04325711
Start Date
April 24 2020
End Date
April 12 2021
Last Update
January 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, China